(Long Post) Tues when I posted \"$FUSZ likely to see .40\'s next

New Post Public Reply Private Reply Replies (1) Message Board
sovntm
373
$FUSZ was $0.63 then, I was hoping that maybe some of you would follow along w/me. I mgs'd a few guys on Twitter at the time. So other's here can vouch for me.

I sold the .65's & .63's Monday. Someone hit me on the bid and sold me the $0.434's & 44's this morning.

Low .30's - mid .20's is the next stop. It's in the bag already

On these pre-revenue story stocks, one generally has to buy and sell them many many times along the way getting where they're going, regardless of where the initial purchase was.

Otherwise, it can be a long, disheartening wait, often to the point where people "throw-in-towel," and sell in disgust waiting for the sales that impatient shareholders think should just immediately materialize.

It rarely ever works that way. In fact, it never works that way.

Building material revenues in brand new company w/new technology always, always, always takes a lot more time than you think. Even managment is likely wrong, optimistic, but likely wrong. There is always significant lag time between product release and material sales numbers in the start-up world.

Just because there are signed marketing agreements doesn't guarantee immediate consumer uptake. The marketplace can be a fickle, bipolar, unpredictable bitch.

That's why a very robust, talented sales force is critical for young company's w/young, unproven technology. But that is hard to find, even harder to build out an effective sales team.

And expecting the 3rd party marketing company's sales force to drive sales is terribly unrealistic for a whole variety of reasons I don't have time to get into now.

You'll notice daily trading volume is dropping off fast. That means the story is known and whoever was going to buy on the story has already bought on the story.

New marketing partnership news releases, when they come, will provide small short bursts in price action. Though as soon as the volume dries up again, price will drop off again. Execution and sales is the only thing that's going to drive price now.

From a Corporate Finance perspective, at some point when there are actually sales numbers, there will have to be a reverse split, among many other things. 120M shares outstanding, and counting is not sustainable. Some would suggest it's irresponsible. But that's how young companies incentivize talent to work for peanuts. So, shares outstanding is likely to grow quite a bit more. The financial picture is going to get a lot worse before it gets better.

For those of you who have never run a start-up, or don't have an Investment Banking background just do the math on what kind of revenue it would take to drive that many shares using a simple "price-to-sales" number. Then compare that number to other start-ups to see what they're up against in the marketplace competing for investor capital. PSR is a decent way to value a new, growing (assuming there is growth) pre-profit companies.

I'm in the Financial District in Beverly Hills, maybe 15mins from FUSZ corporate offices. I'll eventually go see the team over there when I have the time.

I'd better stop now. Don't want to blow you guys outta the water with too much "real-life in a start-up" info. I'll drop in from time to time. Be careful out there
2
Scroll down for more posts ▼

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 31

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 655

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 406

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 83

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 18

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 55

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 45

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

VivoPower Innovates with XRP-Focused Treasury Strategy

Updated Category News Views 359

VivoPower's Transformational XRP Strategy VivoPower International PLC (NASDAQ: VVPR) has recently embarked on a groundbreaking journey by announcing a new strategy centered on the digital asset XRP. The company is positioning itself as the first publicly traded entity to implement an XRP-focused digital asset treasury. This innovative approach is not only exciting for...

Continue Reading
Recognizing Excellence in Product Stewardship for 2024

Updated Category News Views 114

Celebrating Product Stewardship Excellence The Product Stewardship Society has announced a significant honor for 2024—Lynn L. Bergeson has been named the recipient of the prestigious Allan K. Fleeger Distinguished Service Award. This esteemed award has been established to acknowledge the remarkable contributions of individual product stewards who have played crucial...

Continue Reading
Gold Hits New Heights Amid Tensions and Election Uncertainty

Updated Category News Views 163

Gold Prices Surge to Record Heights In recent trading, gold prices have reached unprecedented levels, reflecting a significant rise driven by various factors, including political uncertainties and ongoing international conflicts. As anticipation surrounding a highly competitive U.S. presidential election grows, along with persistent tensions in regions such as the Middle...

Continue Reading
Paul Jebely Joins Sterlington as Aviation Law Vice Chair

Updated Category News Views 257

Paul Jebely Joins Sterlington as New Partner Sterlington PLLC is excited to announce that Paul Jebely has joined the firm as their new Partner and Vice Chair of International, marking a crucial advancement in their aviation law practice. Jebely is not just any attorney; he is a globally recognized authority in private aviation law, especially known for his work with...

Continue Reading
William James Wartinbee III Executes Significant Sell Strategy

Updated Category News Views 62

William James Wartinbee III Implements Key Sell Strategy In a noteworthy insider sale, William James Wartinbee III, the Executive Vice President at Gartner (IT), has sold 210 shares of the company. This transaction was documented in a Form 4 filing with the U.S. Securities and Exchange Commission, and the sale was valued at about $103,275. Examining Gartner's Current...

Continue Reading